AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2007, for Hemispherx Biopharma, Inc. The company is a biopharmaceutical firm focused on immune system-enhancing technologies. Its primary assets include the FDA-approved product Alferon N Injection (for genital warts) and the investigational drug Ampligen (undergoing Phase III trials for Chronic Fatigue Syndrome and influenza). The company operates with an accumulated deficit and relies on equity financing and clinical trial revenues.

Key Financial Metrics (Six Months Ended June 30, 2007)

Note: All financial figures are in thousands unless otherwise noted.

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the six months ended June 30, 2007, decreased by 18% to $9.0 million compared to $11.0 million in the prior year period. This improvement was driven by lower General & Administrative (G&A) expenses and reduced interest/financing costs.
• Debt Elimination: In June 2007, the company retired all remaining convertible debentures (approx. $4.1 million outstanding). Approximately $2.6 million was paid in cash, with the remainder covered by an advance receivable held as collateral. Consequently, interest expense and financing costs dropped significantly.
• Revenue Stability: Total revenues remained relatively flat at $489,000 (vs. $483,000 in 2006). Sales of Alferon N Injection increased due to a price hike, offsetting a decline in Ampligen cost-recovery clinical program sales.
• Expense Management: G&A expenses fell by 36% ($1.85 million reduction) primarily due to a decrease in non-cash equity-based compensation and lower accounting fees related to prior financial restatements.
• R&D Increase: Research and Development costs rose by $692,000 (14%) to $5.7 million, attributed to increased consultant usage for the Ampligen New Drug Application (NDA) preparation.

Guidance, Outlook, and Risks

• Liquidity Outlook: As of July 31, 2007, the company held approximately $19.9 million in cash and short-term investments. Management anticipates these funds will cover operating requirements for the next 15 months.
• Financing Strategy: The company continues to utilize a common stock purchase agreement with Fusion Capital, which allows for the purchase of up to $50 million of stock over 25 months. Through July 31, 2007, approximately $18.4 million had been raised under this agreement.
• Regulatory Status: The company is preparing to file an NDA for Ampligen for Chronic Fatigue Syndrome. The timeline for FDA review and approval remains uncertain. Clinical trials for Ampligen as an influenza adjuvant are ongoing in Australia and Japan.
• Key Risks:
  • Product Development: No assurance that Ampligen will receive FDA approval or be commercially viable.
  • Capital Requirements: Future profitability is uncertain; additional financing may be required, potentially causing significant dilution.
  • Competition: Alferon N Injection faces competition from established interferon products and topical treatments.
  • Supply Chain: Lack of long-term agreements for essential raw materials (e.g., human white blood cells for Alferon).

Investor Verification Checklist

• Debt Retirement Confirmation: Verify the complete extinguishment of the $4.1 million convertible debenture debt and the accounting treatment of the collateral receivable.
• NDA Timeline: Monitor updates on the status of the Ampligen New Drug Application filing and FDA review milestones.
• Equity Dilution: Track the rate of share issuance under the Fusion Capital purchase agreement and its impact on earnings per share.
• Cash Burn Rate: Assess whether the projected 15-month runway remains accurate given the increased R&D spending on the NDA.
• Revenue Mix: Evaluate the sustainability of Alferon N Injection sales given the noted decline in unit volume despite price increases.